acquired
Stage
2
Investors
About
BerGenBio developed first-in-class AXL inhibitors targeting aggressive diseases, particularly in oncology, before merging with Oncoinvent ASA in 2025.
Explore BerGenBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.